Venous thromboembolic diseases: diagnosis, management and thrombophilia testing

any of the conclusions from the economic model. The committee recognised that there are circumstances in which LMWH is the most suitable treatment option and agreed that it could be considered when this is the case. They were aware that LMWH with a VKA is often impractical for people with active cancer because of difficulties with international normalised ratio (INR) monitoring and maintaining INR within the therapeutic range. They agreed that it is less clinically effective than LMWH alone but is less costly and remains a suitable option in some circumstances. Anticoagulation treatment for people with DVT or PE and triple positive antiphospholipid syndrome The committee were aware of an MHRA safety alert warning of an increase in VTE recurrence in people with diagnosed triple positive antiphospholipid syndrome taking a DOAC compared with those taking LMWH and a VKA. Although people with antiphospholipid syndrome were not included in the evidence review, the committee agreed that it is important to include a recommendation highlighting the need to offer LMWH with a VKA to this group. Anticoagulation treatment for DVT or PE in people who use intravenous drugs VTE can be difficult to treat in people who use intravenous drugs. They often
